Glaxo Official Memo Urged Scientists to Withhold Information About Paxil's Risks, Trial Hears; Pharmaceutical Industry Today Offers Complete News Coverage

WASHINGTON, September 16 - /EIN Presswire/ Antidepressant drug Paxil, which generated about 2.1% of GlaxoSmithKline's total revenue last year, has been known to cause birth defects, but the world's second-biggest drugmaker hid its risks to pump up profits, a Philadelphia court has heard.

According to available information, Glaxo failed to properly test the drug and urged scientists to conceal Paxil's risks. The Philadelphia trial is the first of more than 600 cases against the London-based company.

Are you satisfied with the way your regular news sources report on these important stories? If not, try Pharmaceutical Industry Today (http://pharmaceuticals.einnews.com/), for free, to see what you may have been missing.

See:
-- GlaxoSmithKline News - http://pharmaceuticals.einnews.com/news/glaxosmithkline
-- Paxil News - http://pharmaceuticals.einnews.com/news/paxil
-- Latest Pharmaceutical News - http://pharmaceuticals.einnews.com/

For a free trial to Pharmaceutical Industry Today, go to: http://pharmaceuticals.einnews.com/users/register.php

About EIN Presswire - http://www.einpresswire.com
EIN Presswire is a news-syndication solution that distributes news to more than 10 million visitors annually at EIN News and millions more through its press release distribution partners. A news source for leading journalists, decision-makers and industry professionals worldwide, EIN Presswire targets press releases to a wide array of worldwide business professionals in more than 80 different industries. EIN Presswire also offers affiliate network opportunities and news distribution to tens of thousands of news subscribers daily. Read the newest business news at http://www.einpresswire.com and the latest world news in more than 80 different industries at http://www.einnews.com


Contact:

EIN News
press@einnews.com
Tel: +1 202 657 5158
Fax: +1 202 478 2767
http://www.einnews.com/